Boston, MA -- (SBWIRE) -- 12/26/2012 --
Global Markets Direct's, 'Other Dermatological Disorders - Pipeline
Review, H2 2012', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic
development for Other Dermatological Disorders, complete with latest
updates, and special features on late-stage and discontinued projects.
It also reviews key players involved in the therapeutic development for
Other Dermatological Disorders. Other Dermatological Disorders -
Pipeline Review, Half Year is built using data and information sourced
from Global Markets Direct's proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Other Dermatological Disorders.
- A review of the Other Dermatological Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Dermatological Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to Get this Report
- Identify and understand important and diverse types of therapeutics under development for Other Dermatological Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Dermatological Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Other Dermatological Disorders.
- A review of the Other Dermatological Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Dermatological Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to Get this Report
- Identify and understand important and diverse types of therapeutics under development for Other Dermatological Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Dermatological Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
http://www.sbwire.com/press-releases/other-dermatological-disorders-pipeline-review-h2-2012-now-available-at-fast-market-research-188632.htm
Nenhum comentário:
Postar um comentário